Previous 10 | Next 10 |
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has partnered with a North American biopharmaceutical company to create the industry's first commercial hMPV human challenge ...
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after releasing audited results for 2022 - a year that he describes as "transformational" for the specialist contract research organisation. Khan gives his highlights from the results befor...
(NewsDirect) hVIVO PLC (AIM:HVO) Director of Business Development for Europe and Asia Egle Pavyde speaks to Proactive's Thomas Warner after announcing the company's second contract win of the year in the Asia-Pacific region. Pavide reveals more details about the contract and says she is delig...
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Proactive's Thomas Warner after releasing a trading update for 2022 that shows the specialist contract research organisation achieved "record results" in 2022. Khan reveals the reasons for the improvement in the performance of...
(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.
Danish biotech firm, Orphazyme (NASDAQ:ORPH) said it will submit the enclosed proposal for a statutory restructuring plan to the Danish Maritime and Commercial High Court and to its known creditors, under section 11 c of the Danish Insolvency Act. As part of the restructuring ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orphazyme (NASDAQ: ORPH ) is falling after the drugmaker announced today that it would delist its American Depositary Shares. The company said that it had started the delisting process and noted that it will take effe...
Danish biotech, Orphazyme (NASDAQ:ORPH) announced on Tuesday that the company decided to withdraw the European Marketing Authorization Application for arimoclomol for the treatment of Niemann-Pick disease Type C (NPC). The decision followed a negative Trend Vote issued by the Committee for Me...
Orphazyme (NASDAQ:ORPH) said the Danish Maritime and Commercial High Court began restructuring proceedings of the company on March 11. Earlier in March the company's board decided to file a petition for an in-court restructuring of Orphazyme. The company had also decided to delist its st...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orphazyme ( NASDAQ: ORPH ) stock is up more than 40% today on no news, raising speculation that investors are targeting shares as a meme play. Source: motorolka / Shutterstock.com The rise in ORPH stock is es...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...